Glycosmedia Weekly Diabetes News - 12/18/2020

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease:

Dapagliflozin reduces the risks of major adverse kidney and cardiovascular events and all-cause mortality in patients with diabetic and non-diabetic chronic kidney disease (The Lancet)

Widespread sensory neuropathy in diabetic patients hospitalized with severe COVID-19 infection

Severe COVID-19 infection with hypoxemia is associated with neuropathic symptoms and widespread sensory dysfunction in patients with DM (Diabetes Research and Clinical Practice)

Diabetes (type 1 and type 2) in children and young people: diagnosis and management

This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18 (NICE)

Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal disease

In this multinational observational study, SGLT2i was associated with a lower risk of HF and CKD versus DPP4i in patients with type 2 diabetes otherwise free from both cardiovascular and renal disease (Diabetes, Obesity and Metabolism)

Potential unrealized mortality benefit of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transport‐2 inhibitors

This analysis indicates unrealized opportunities to reduce mortality in selected veterans with T2D and CAD via increased GLP‐1RA and SGLT2i use (Diabetes, Obesity and Metabolism)

Prediction of Heart Failure Outcomes in Patients with Type 2 Diabetes Mellitus: Validation of the TRS‐HFDM Score in the ACCORD Trial

The TRS‐HFDM discriminates for HF specific risk among people with T2DM. Using the TRS‐HFDM to identify those who maximally benefit from therapies that reduce HF risk warrants evaluation (Diabetes, Obesity and Metabolism)

Comparative Efficacy of Dual and Single Initiation of Add-On Oral Antihyperglycemic Agents in Type 2 Diabetes Uncontrolled on Metformin Alone: A Systematic Literature Review and Network Meta-Analysis

For reduction of HbA1c, weight, and SBP in patients uncontrolled on metformin, add-on dual AHAs showed greater improvement compared to single AHAs. These findings can further inform the treatment of T2DM patients uncontrolled on metformin (Diabetes Therapy)